OnabotulinumtoxinA and Midurethral Sling have Comparable Outcomes for Mixed Urinary Incontinence Treatment: JAMA Medha Baranwal15 May 2025 8:45 PM ISTUSA: Researchers have found in a new study that there were no significant differences in outcomes between females treated with onabotulinumtoxinA and...
Anti-CGRP monoclonal antibodies may not increase CVD risks among migraine patients compared to onabotulinumtoxinA: JAMA Medha Baranwal9 Jan 2025 8:30 PM ISTUSA: A recent cohort study published in JAMA Neurology has provided new insights into the cardiovascular safety of anti-CGRP monoclonal antibodies...
FDA approves Botox Cosmetic for Moderate to Severe Platysma Bands Dr. Kamal Kant Kohli25 Oct 2024 8:15 AM ISTThe Food and Drug Administration (FDA) has approved Botox Cosmetic (onabotulinumtoxinA) for temporary improvement of moderate to severe platysma...
OnabotulinumtoxinA efficacious short term treatment for microstomia in scleroderma Dr. Shravani Dali27 July 2023 8:00 PM ISTOnabotulinumtoxinA efficacious short term treatment for microstomia in scleroderma suggests a new study published in the Journal of the American...
Botox improves patient satisfaction, appearance-related psychological impact for treating upper facial lines: Study Medha Baranwal18 Nov 2022 8:00 PM ISTUSA: A recent study in Dermatologic Surgery has shown that patients with a lasting response to onabotulinumtoxinA report clinically meaningful...
BTX-A for overactive bladder tied to incomplete emptying and UTI risk: Study Medical Dialogues Editorial Team14 Feb 2022 9:00 AM ISTUSA: In a new study conducted by William Stuart Reynolds and team, it was found that incomplete emptying and urinary tract infection (UTI) were...
Botox receives FDA approval for neurogenic detrusor overactivity in children Medha Baranwal12 Feb 2021 7:30 PM ISTUSA: The US Food and Drug Administration (FDA) has given its approval to AbbVie's onabotulinumtoxin (BOTOX). The approval is for the treatment of...
Mylan, Revance to Advance Development Program for Biosimilar to BOTOX Ruchika Sharma5 Jun 2020 9:00 AM ISTMylan and Revance signed a collaboration and license agreement in February 2018 for the development and regulatory approval of a biosimilar to BOTOX,...
